ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lardot, C
Right arrow Articles by Lison, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lardot, C
Right arrow Articles by Lison, D
Eur Respir J 1998; 11: 912-921
Copyright © ERS Journals Ltd 1998


Original Articles

Expression of plasminogen activator inhibitors type-1 and type-2 in the mouse lung after administration of crystalline silica

C Lardot, M Heusterpreute, P Mertens, M Philippe, and D Lison

Altered expression of plasminogen activator inhibitors (PAIs) is of potential relevance to the process of lung fibrosis. To clarify the involvement of PAIs in interstitial lung diseases, we examined whether alterations in PAI-1 and PAI-2 were induced in response to a single intratracheal administration of a fibrosing dose of crystalline silica in mice (5 mg x animal(-1)). The time course of changes in PAI activity and PAI-1 protein were characterized in bronchoalveolar lavage fluid (BALF) and changes in PAI-1 and PAI-2 messenger ribonucleic acid (mRNAs) were monitored by reverse transcriptase polymerase chain reaction (RT-PCR) in BALF cells and lung tissue up to the fibrotic stage of the disease. Substantial levels of PAI activity were found in BALF of control animals, whereas no PAI-1 protein was detected. In response to silica treatment, we observed an acute increase of PAI activity and PAI-1 protein levels in BALF (day 1), associated with an induction of PAI-1 and PAI-2 mRNA levels in lung tissue. In alveolar macrophages, silica treatment induced a persistent upregulation of PAI-2 mRNA only. One month after silica treatment, PAI activity was undetectable in BALF while substantial PAI activity was still present in controls. At the same time point, sustained upregulation of PAI-1 and PAI- 2 mRNAs was, however, noted in lung tissue of animals treated with silica. These findings support the possible implication of PAIs in the remodelling process induced by silica in the lung.


This article has been cited by other articles:


Home page
CLIN APPL THROMB HEMOSTHome page
B. Tutluoglu, C. B. Gurel, S. B. Ozdas, B. Musellim, S. Erturan, A. N. Anakkaya, G. Kilinc, and T. Ulutin
Platelet Function and Fibrinolytic Activity in Patients with Bronchial Asthma
Clinical and Applied Thrombosis/Hemostasis, January 1, 2005; 11(1): 77 - 81.
[Abstract] [PDF]


Home page
J. Immunol.Home page
S. H. Cho, S. W. Tam, S. Demissie-Sanders, S. A. Filler, and C. K. Oh
Production of Plasminogen Activator Inhibitor-1 by Human Mast Cells and Its Possible Role in Asthma
J. Immunol., September 15, 2000; 165(6): 3154 - 3161.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. PÉREZ-RAMOS, M. de LOURDES SEGURA-VALDEZ, B. VANDA, M. SELMAN, and A. PARDO
Matrix Metalloproteinases 2, 9, and 13, and Tissue Inhibitors of Metalloproteinases 1 and 2 in Experimental Lung Silicosis
Am. J. Respir. Crit. Care Med., October 1, 1999; 160(4): 1274 - 1282.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the European Respiratory Society.